Editing Oxycodone (section)

==== Canada ====
Oxycodone is a controlled substance under Schedule I of the [[Controlled Drugs and Substances Act]] (CDSA).<ref name="CanadaCDSA">{{cite web |last=Canada Department of Justice |title=Controlled Drugs and Substances Act (1996, c. 19) |date=27 February 2009 |url=http://laws.justice.gc.ca/en/ShowFullDoc/cs/C-38.8///en |access-date=23 March 2009 |archive-date=5 June 2011 |archive-url=https://web.archive.org/web/20110605062114/http://laws.justice.gc.ca/en/ShowFullDoc/cs/C-38.8///en |url-status=dead }}</ref>

[[File:Oxycocet.jpg|thumb|Canadian oxycodone HCL/acetaminophen 5/325 mg tablet]]

In February 2012, Ontario passed legislation to allow the expansion of an already existing drug-tracking system for publicly funded drugs to include those that are privately insured. This database will function to identify and monitor patient's attempts to seek prescriptions from multiple doctors or retrieve them from multiple pharmacies. Other provinces have proposed similar legislation, while some, such as Nova Scotia, have legislation already in effect for monitoring prescription drug use. These changes have coincided with other changes in Ontario's legislation to target the misuse of painkillers and high addiction rates to drugs such as oxycodone. As of 29 February 2012, Ontario passed legislation delisting oxycodone from the province's public drug benefit program. This was a first for any province to delist a drug based on addictive properties. The new law prohibits prescriptions for OxyNeo except to certain patients under the Exceptional Access Program including palliative care and in other extenuating circumstances. Patients already prescribed oxycodone will receive coverage for an additional year for OxyNeo, and after that, it will be disallowed unless designated under the exceptional access program.<ref>Olgilvie, Megan. [https://www.thestar.com/news/canada/article/1133247--ontario-to-delist-oxycontin-and-its-substitute-from-drug-benefit-program "Ontario delisting OxyContin and its substitute from drug benefit program"] {{Webarchive|url=https://web.archive.org/web/20120623022441/http://www.thestar.com/news/canada/article/1133247--ontario-to-delist-oxycontin-and-its-substitute-from-drug-benefit-program |date=23 June 2012 }} Toronto Star (17 February 2012)</ref>

Much of the legislative activity has stemmed from Purdue Pharma's decision in 2011 to begin a modification of OxyContin's composition to make it more difficult to crush for snorting or injecting. The new formulation, OxyNeo, is intended to be preventive in this regard and retain its effectiveness as a painkiller. Since introducing its ''Narcotics Safety and Awareness Act'', Ontario has committed to focusing on drug addiction, particularly in the monitoring and identification of problem opioid prescriptions, as well as the education of patients, doctors, and pharmacists.<ref>[http://www.health.gov.on.ca/en/public/programs/drugs/ons/ons_legislation.aspx Narcotics Safety and Awareness Act] {{Webarchive|url=https://web.archive.org/web/20200607162003/http://health.gov.on.ca/en/public/programs/drugs/ons/ons_legislation.aspx |date=7 June 2020 }}. 2010. Ministry of Health and Long Term Care.</ref> This Act, introduced in 2010, commits to the establishment of a unified database to fulfil this intention.<ref>{{cite web |date=22 February 2012 |url=http://healthydebate.ca/2011/02/_mailpress_mailing_list_healthydebate-news/opioids | vauthors = Dhalla I, Born K |website=healthydebate.ca |title=Opioids |archive-url=https://web.archive.org/web/20150321100652/http://healthydebate.ca/2011/02/_mailpress_mailing_list_healthydebate-news/opioids |archive-date=21 March 2015 }}</ref> Both the public and medical community have received the legislation positively, though concerns about the ramifications of legal changes have been expressed. Because laws are largely provincially regulated, many speculate a national strategy is needed to prevent smuggling across provincial borders from jurisdictions with looser restrictions.<ref>{{cite web | url = http://www.huffingtonpost.ca/2012/02/20/ontario-oxycontin-rules-national-regulations_n_1288375.html | title = Ontario OxyContin Rules: New Restrictions Applauded But National Rules Needed | archive-url = https://web.archive.org/web/20200923061253/https://www.huffingtonpost.ca/2012/02/20/ontario-oxycontin-rules-national-regulations_n_1288375.html | archive-date=23 September 2020 | work = Huffington Post. Canadian Press | date = 20 February 2012 }}</ref>

In 2015, Purdue Pharma's abuse-resistant OxyNEO and six generic versions of OxyContin had been on the Canada-wide approved list for prescriptions since 2012. In June 2015, then-federal Minister of Health Rona Ambrose announced that within three years, all oxycodone products sold in Canada would need to be tamper-resistant. Some experts warned that the generic product manufacturers may not have the technology to achieve that goal, possibly giving Purdue Pharma a monopoly on this opiate.<ref>{{cite news |vauthors=Weeks C, Howlett K |date=4 August 2015 |title=New oxycodone rules would give drug maker a monopoly in Canada, experts warn |url=https://www.theglobeandmail.com/news/national/new-oxycodone-rules-would-give-drug-maker-a-monoply-in-canada-experts-warn/article25820214/ |newspaper=Globe and Mail |location=Toronto, Ontario |access-date=15 December 2015 |archive-date=22 December 2015 |archive-url=https://web.archive.org/web/20151222143809/http://www.theglobeandmail.com/news/national/new-oxycodone-rules-would-give-drug-maker-a-monoply-in-canada-experts-warn/article25820214/ |url-status=live }}</ref>

Several class-action suits across Canada have been launched against the Purdue group of companies and affiliates. Claimants argue the pharmaceutical manufacturers did not meet a standard of care and were negligent in doing so. These lawsuits reference earlier judgments in the United States, which held that Purdue was liable for wrongful marketing practices and misbranding. Since 2007, the Purdue companies have paid over CAN$650 million in settling litigation or facing criminal fines.<!-- <ref>Martin, Kevin. {{usurped|1=[https://archive.today/20120709211050/http://chealth.canoe.ca/channel_health_news_details.asp?channel_id=131&relation_id=1883&news_channel_id=131&news_id=26055&rid Lawsuit attacks OxyContin use]}}. C-Health. Sun Media (8 August 2008)</ref> This article is about alcohol use disorder. -->